Cart
sales@molnova.com
Tulisokibart
CAS No. 2648504-55-4
Tulisokibart( —— )
Catalog No. M37264 CAS No. 2648504-55-4
Tulisokibart (PRA023) is a humanized anti-TNFSF15 monoclonal antibody used to study colon cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 388 | Get Quote |
|
| 5MG | 713 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameTulisokibart
-
NoteResearch use only, not for human use.
-
Brief DescriptionTulisokibart (PRA023) is a humanized anti-TNFSF15 monoclonal antibody used to study colon cancer.
-
DescriptionTulisokibart (PRA023) is a humanized IgG1-κ monoclonal antibody targeting to TNFSF15/TL1A. Tulisokibart can be used to study a variety of inflammatory/fibrotic diseases, such as Crohn's Disease (CD).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetTNF
-
RecptorTNF
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2648504-55-4
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Feagan B G, Sands B, Siegel C A, et al. DOP87 The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn’s Disease: Phase 2a APOLLO-CD Study Results[J]. Journal of Crohn's and Colitis, 2023, 17(Supplement_1): i162-i164.
molnova catalog
related products
-
Zigakibart
Zigakibart (BION-1301) is a humanized monoclonal antibody targeting TNFSF13 with anti-inflammatory activity for the study of immunoglobulin A nephropathy (IgAN).
-
Lenalidomide
Lenalidomide (initially known as CC-5013 and marketed as Revlimid? by Celgene) is a derivative of thalidomide introduced in 2004.
-
Varlilumab
Varlilumab (CDX-1127) is a novel human IgG1 anti-CD27 monoclonal antibody with antitumor activity, useful for studying advanced solid tumors.
